New Hope for PD: Gene Therapy Blocks Dyskinesia in Monkeys

A recent study in aged Parkinsonian macaques shows that gene therapy targeting CaV1.3 calcium channels may prevent and reverse levodopa-induced dyskinesia (LID), without reducing the benefits of levodopa itself. What They Did: Researchers injected aged PD monkeys with a gene therapy (AAV-shRNA) that silences the CaV1.3 calcium channel in the brain's motor control center (putamen). What They Found: Dyskinesia was nearly eliminated. Control monkeys developed severe involuntary movements, but the treated monkeys showed almost none. Levodopa still worked. The therapy preserved the motor benefit of levodopa without triggering side effects. Motor function improved even without medication, suggesting possible neuroprotection. Why It Matters: This gene therapy targets a root mechanism in PD—calcium overload in dopamine neurons—and may be one of the strongest disease-modifying approaches under development. Not in Humans Yet: This therapy is still in preclinical stages, but human trials could begin in a few years.